Trials / Conditions / Stage III Squamous Cell Carcinoma of the Paranasal Sinus and Nasal Cavity

Stage III Squamous Cell Carcinoma of the Paranasal Sinus and Nasal Cavity

13 registered clinical trials studyying Stage III Squamous Cell Carcinoma of the Paranasal Sinus and Nasal Cavity.

Status	Trial	Sponsor	Phase
Withdrawn	Entolimod in Treating Patients With Stage III-IV Squamous Cell Head and Neck Cancer Receiving Cisplatin and Ra NCT01728480	Roswell Park Cancer Institute	Phase 1
Withdrawn	Botanical Therapy in Treating Mucositis in Patients With Head and Neck Cancer Who Have Undergone Chemoradiatio NCT01674374	Roswell Park Cancer Institute	Phase 2
Terminated	Talactoferrin in Treating Patients With Relapsed or Refractory Non-Small Cell Lung Cancer or Squamous Cell Hea NCT01528137	Stanford University	Phase 1
Completed	TLR8 Agonist VTX-2337 and Cetuximab in Treating Patients With Locally Advanced, Recurrent, or Metastatic Squam NCT01334177	University of Washington	Phase 1
Terminated	Selenomethionine in Reducing Mucositis in Patients With Locally Advanced Head and Neck Cancer Who Are Receivin NCT01682031	Roswell Park Cancer Institute	Phase 2
Terminated	Sunitinib, Cetuximab, and Radiation Therapy in Treating Patients With Locally Advanced or Recurrent Squamous C NCT00906360	National Cancer Institute (NCI)	Phase 1
Completed	Saracatinib in Treating Patients With Recurrent or Metastatic Head and Neck Cancer NCT00513435	National Cancer Institute (NCI)	Phase 2
Completed	Bevacizumab in Reducing CNS Side Effects in Patients Who Have Undergone Radiation Therapy to the Brain for Pri NCT00492089	National Cancer Institute (NCI)	Phase 2
Completed	Erlotinib and Cetuximab With or Without Bevacizumab in Treating Patients With Metastatic or Unresectable Kidne NCT00101348	National Cancer Institute (NCI)	Phase 1 / Phase 2
Completed	Alvespimycin Hydrochloride in Treating Patients With Metastatic or Unresectable Solid Tumors NCT00089362	National Cancer Institute (NCI)	Phase 1
Terminated	Intratumoral PV701 in Treating Patients With Advanced or Recurrent Unresectable Squamous Cell Carcinoma of the NCT00081211	National Cancer Institute (NCI)	Phase 1
Completed	Erlotinib Plus Docetaxel in Treating Patients With Locally Advanced, Metastatic, or Recurrent Head and Neck Ca NCT00055770	National Cancer Institute (NCI)	Phase 1 / Phase 2
Completed	Bevacizumab, Fluorouracil, and Hydroxyurea Plus Radiation Therapy in Treating Patients With Advanced Head and NCT00023959	National Cancer Institute (NCI)	Phase 1